As of 2026-08-09, the EV/EBITDA ratio of Cytokinetics Inc (CYTK) is -18.02. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CYTK's latest enterprise value is 11,439.81 mil USD. CYTK's TTM EBITDA according to its financial statements is -634.74 mil USD. Dividing these 2 quantities gives us the above CYTK EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.8x - 18.2x | 17.0x |
| Forward P/E multiples | 18.2x - 22.8x | 22.0x |
| Fair Price | (92.92) - (92.82) | (98.91) |
| Upside | -221.0% - -220.9% | -228.9% |
| Date | EV/EBITDA |
| 2026-08-07 | -18.02 |
| 2026-08-06 | -19.01 |
| 2026-08-05 | -18.47 |
| 2026-08-04 | -18.42 |
| 2026-08-03 | -17.96 |
| 2026-07-31 | -18.10 |
| 2026-07-30 | -18.80 |
| 2026-07-29 | -18.37 |
| 2026-07-28 | -18.60 |
| 2026-07-27 | -18.85 |
| 2026-07-24 | -18.87 |
| 2026-07-23 | -19.12 |
| 2026-07-22 | -19.18 |
| 2026-07-21 | -18.95 |
| 2026-07-20 | -18.52 |
| 2026-07-17 | -18.75 |
| 2026-07-16 | -18.79 |
| 2026-07-15 | -19.27 |
| 2026-07-14 | -19.13 |
| 2026-07-13 | -19.19 |
| 2026-07-10 | -19.76 |
| 2026-07-09 | -20.01 |
| 2026-07-08 | -19.76 |
| 2026-07-07 | -19.90 |
| 2026-07-06 | -19.90 |
| 2026-07-02 | -20.10 |
| 2026-07-01 | -19.84 |
| 2026-06-30 | -19.82 |
| 2026-06-29 | -20.27 |
| 2026-06-26 | -19.18 |
| 2026-06-25 | -18.89 |
| 2026-06-24 | -18.97 |
| 2026-06-23 | -18.72 |
| 2026-06-22 | -18.54 |
| 2026-06-18 | -18.45 |
| 2026-06-17 | -18.31 |
| 2026-06-16 | -17.69 |
| 2026-06-15 | -16.87 |
| 2026-06-12 | -16.61 |
| 2026-06-11 | -16.42 |
| 2026-06-10 | -15.95 |
| 2026-06-09 | -16.25 |
| 2026-06-08 | -16.13 |
| 2026-06-05 | -16.89 |
| 2026-06-04 | -17.07 |
| 2026-06-03 | -16.73 |
| 2026-06-02 | -16.77 |
| 2026-06-01 | -17.36 |
| 2026-05-29 | -18.02 |
| 2026-05-28 | -18.03 |